AI Article Synopsis
- The study examines the infection rates associated with transrectal ultrasound-guided prostate needle biopsies across multiple Australian centers to assess its safety as a diagnostic method for prostate cancer.
- Data were collected from seven centers, revealing that out of 12,240 biopsies, the overall infective complication rate was low at 0.86%, with no reported deaths and very few ICU admissions due to sepsis.
- While the findings suggest that TRUS biopsy is a safe procedure, further research directly comparing it to the trans-perineal approach is needed before making any shifts in recommended techniques.
Article Abstract
Purpose: Worldwide, transrectal ultrasound-guided prostate needle remains the most common method of diagnosing prostate cancer. Due to high infective complications reported, some have suggested it is now time to abandon this technique in preference of a trans-perineal approach. The aim of this study was to report on the infection rates following transrectal ultrasound-guided prostate needle biopsy in multiple Australian centres.
Materials And Methods: Data were collected from seven Australian centres across four states and territories that undertake transrectal ultrasound-guided prostate needle biopsies for the diagnosis of prostate cancer, including major metropolitan and regional centres. In four centres, the data were collected prospectively. Rates of readmissions due to infection, urosepsis resulting in intensive care admission and mortality were recorded.
Results: 12,240 prostate biopsies were performed in seven Australian centres between July 1998 and December 2020. There were 105 readmissions for infective complications with rates between centres ranging from 0.19 to 2.60% and an overall rate of 0.86%. Admission to intensive care with sepsis ranged from 0 to 0.23% and overall 0.03%. There was no mortality in the 12,240 cases.
Conclusion: Infective complications following transrectal ultrasound-guided prostate needle biopsies are very low, occurring in less than 1% of 12,240 biopsies. Though this study included a combination of both prospective and retrospective data and did not offer a comparison with a trans-perineal approach, TRUS prostate biopsy is a safe means of obtaining a prostate cancer diagnosis. Further prospective studies directly comparing the techniques are required prior to abandoning TRUS based upon infectious complications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00345-021-03862-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ultrasound radiomics model based on grayscale transrectal ultrasound-guided biopsy for diagnosing prostate cancer and predicting distant metastasis.
Int Urol Nephrol
January 2025
Department of Ultrasound, The First College of Clinical Medical Science, China Three Gorges University, Yichang Central People's Hospital, No. 2 Jiefang Road, Xiling District, Yichang, Hubei, China.
Objective: A prostate ultrasound (US) imaging omics model was established to assess its effectiveness in diagnosing prostate cancer (PCa), predicting Gleason score (GS), and determining the likelihood of distant metastasis.
Methods: US images of patients with prostate pathology confirmed by biopsy or surgery at our hospital were retrospectively analyzed. Regions of interest (ROI) segmentation, feature extraction, feature screening, and the construction and training of the radiomics model were performed.
Construction of a clinically significant prostate cancer risk prediction model based on traditional diagnostic methods.
Front Oncol
December 2024
Urology 2nd Department, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Objectives: to construct a prediction model for clinically significant prostate cancer (csPCa) based on prostate-specific antigen (PSA) levels, digital rectal examination (DRE), and transrectal ultrasonography (TRUS).
Methods: We retrospectively analysed 1196 Asian patients who underwent transrectal ultrasound-guided biopsy (TRUSB) between June 2000 and February 2023. Patients were randomly divided into a training set of 837 cases (70%) and a validation set of 359 patients (30%).
Radiomics of Periprostatic Fat and Tumor Lesion Based on MRI Predicts the Pathological Upgrading of Prostate Cancer from Biopsy to Radical Prostatectomy.
Acad Radiol
December 2024
Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou 35005, China (W-Q.L., Y.W., Z-B.K., B.L., X-H.W., X-Y.H., Z-J.C., J-Y.C., S-H.C., Y-T.X., F.L., D-N.C., Q-S.Z., X-Y.X., N.X.); Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou 350212, China (W-Q.L., Y.W., Z-B.K., B.L., X-H.W., X-Y.H., Z-J.C., J-Y.C., S-H.C., Y-T.X., F.L., D-N.C., Q-S.Z., X-Y.X., N.X.); Fujian Key Laboratory of Precision Medicine for Cancer, the First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China (X-Y.X., N.X.). Electronic address:
Rationale And Objectives: To assess the predictive value of MRI-based radiomics of periprostatic fat (PPF) and tumor lesions for predicting Gleason score (GS) upgrading from biopsy to radical prostatectomy (RP) in prostate cancer (PCa).
Methods: A total of 314 patients with pathologically confirmed prostate cancer (PCa) after radical prostatectomy (RP) were included in the study. The patients were randomly assigned to the training cohort (n = 157) and the validating cohort (n = 157) in a 1:1 ratio.
Outcomes of Systematic Transrectal Ultrasound-Guided Prostate Biopsy Performed by a Surgical Care Practitioner and Implications for Resource-Poor Countries.
Cureus
November 2024
Urology, Peterborough City Hospital, Peterborough, GBR.
Introduction Prostate cancer remains the most prevalent cancer among men and continues to present a significant public health challenge globally. The disease's growing prevalence has heightened the demand for skilled professionals capable of obtaining histological samples for accurate diagnosis, as tissue biopsy remains the cornerstone for diagnosing prostate cancer. Surgical care practitioners have become integral to the surgical team, and their roles have expanded to include performing biopsies.
View Article and Find Full Text PDFCancer detection in patients with prostate-specific antigen levels within the grey zone: can synthetic magnetic resonance imaging aid in the differentiation between prostate cancer and noncancerous lesions?
Quant Imaging Med Surg
December 2024
Department of Radiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Background: The detection of prostate cancer (PCa) via conventional magnetic resonance imaging (MRI) in patients with prostate-specific antigen (PSA) levels within the grey zone remains challenging. Whether synthetic MRI can provide supplementary benefits for the accurate diagnosis of PCa in this specific population is still unknown. This study aims to investigate the diagnostic performance of synthetic MRI for differentiating PCa lesions from noncancerous lesions in patients with PSA levels within the grey zone (4-10 ng/mL).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!